Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.

Autor: Nardinelli L; Tumor Biology Laboratory, Faculty of Medicine, University of São Paulo, Brazil., Sanabani SS, Didone A, Ferreira Pde B, Serpa M, Novaes MM, Marchiani M, Ruiz AL, Lima IS, Chamone Dde A, Bendit I

Publikováno v: Acta haematologica [Acta Haematol] 2012; Vol. 127 (4), pp. 228-34. Date of Electronic Publication: 2012 Apr 13.

Karyotypic and fluorescent in situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms.

Autor: Tanizawa RS; Cytogenetics Laboratory, Serviço de Hematologia do Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo - USP, São Paulo, SP, Brazil., Kumeda CA, de Azevedo Neto RS, Leal Ade M, Ferreira Pde B, Velloso ED

Publikováno v: Revista brasileira de hematologia e hemoterapia [Rev Bras Hematol Hemoter] 2011; Vol. 33 (6), pp. 425-31.

Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.

Autor: Grimm, Daniel¹, Lieb, Jonas¹, Weyer, Veronika², Vollmar, Johanna¹, Darstein, Felix¹, Lautem, Anja³, Hoppe-Lotichius, Maria³, Koch, Sandra¹, Schad, Arno⁴, Schattenberg, Jörn M.¹, Wörns, Marcus A.¹, Weinmann, Arndt¹, Galle, Peter R.¹, Zimmermann, Tim¹ tim.zimmermann@unimedizin-mainz.de

Publikováno v: BMC Cancer. 2/12/2016, Vol. 16, p1-8. 8p. 4 Charts, 2 Graphs.

Handbook of Tumor Syndromes

Autor: Dongyou Liu

Tumors/cancers are characterized by uncontrolled growths of abnormal cells that extend beyond their usual boundaries and disrupt the normal functions of affected organs and systems. While about 75%–80% of tumors/cancers arise sporadically without a